Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 12/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 12/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.32 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16756281 | 0.79 | GPR6 (0.39) | GPR6CDK9SPHK1GRIN1GRIN2B | |
| SCHEMBL16756279 | 0.79 | GPR6 (0.39) | GPR6CDK9SPHK1GRIN1GRIN2B | |
| SCHEMBL16756282 | 0.79 | GPR6 (0.39) | GPR6CDK9SPHK1GRIN1GRIN2B | |
| SCHEMBL16756405 | 0.78 | GPR6 (0.36) | GPR6CDK9SPHK1GRIN1GRIN2B | |
| SCHEMBL16756275 | 0.76 | GRIN1 (0.47) | GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL16756470 | 0.76 | GPR6 (0.37) | GPR6CDK9SPHK1GRIN1GRIN2B | |
| SCHEMBL16756334 | 0.76 | CDK9 (0.36) | GPR6CDK9GRIN1GRIN2BTSHR | |
| SCHEMBL16756407 | 0.73 | HPGD (0.44) | GRIN1GRIN2BTSHRPPARG | |
| SCHEMBL15560797 | 0.71 | GRIN1 (0.41) | GRIN1GRIN2B | |
| SCHEMBL16756385 | 0.71 | GALR3 (0.41) | TSHRPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550737-B2 | TNF -α modulating benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2017-01-24 | — | — | US | disclosed |
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | UCB BIOPHARMA SPRL (BE) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152065-A1 | TNF -Alpha Modulating Benzimidazoles | TNF, TNFRSF1A, NFKBIA | GPR6 2472/4885CDK9 1687/4885SPHK1 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.